explore -WSS

explore

author：hotspot 2025-09-30 18:54:27 - browse：942

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

To hear Sarepta CEO Doug Ingram tell it, the results Monday afternoon from a large trial of its gene therapy for Duchenne muscular dystrophy marked a clear medical breakthrough. “A massive win,” he told investors, that could lead to its approval for all patients with the fatal muscle-wasting disease regardless of age.

And yet the rest of the Duchenne community was more cautious in its enthusiasm. The study — the most rigorous test to date of a technology 30 years in the making — had technically failed, as so many had before it.

“It’s extremely frustrating,” said John Brandsema, a pediatric neurologist at Children’s Hospital of Philadelphia who worked on the study. “When you spend decades trying to bring therapies into the clinic for something so severe and just keep missing over and over again.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Resistance to cancer drugs: A new genetic explanation

focus

hotspot

WSS

Norman Reedus' Daryl Dixon

Stanford president to resign after investigation of research

Transgender sports debate: Physicians say bans are health issue

Resistance to cancer drugs: A new genetic explanation

People with substance use disorder deserve online privacy

Norman Reedus' Daryl Dixon

leisure time

explore

Wikipedia

Trump demands the U.S. pay no more for drugs than other countries … again

New warning issued for rebooking air travel after delays, cancellations

Walensky prepares to leave CDC — and Congress — behind

Chamber of Commerce, DOJ clash in court over drug prices

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Neurocrine congenital adrenal hyperplasia trial succeeds

Duchenne breakthrough therapy leaves behind pioneering families

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Continuity nursing helped my family in our darkest PICU moments

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

entertainment

PBMs drew scrutiny in House hearing — and so did pharma

The unintended consequences of overturning Roe v. Wade

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

Midwives could help bridge maternal health disparities in the U.S.

PBMs drew scrutiny in House hearing — and so did pharma

Plane’s emergency slide plummets from sky, hits Chicago home

leisure time

focus

hotspot

hotspot